Pub Date : 2024-01-11DOI: 10.1016/j.canrad.2023.11.001
J-M Hannoun-Lévi, A Savignoni, J-G Féron, C Malhaire, C Ezzili, A Brédart, P Loap, Y Kirova
For a second ipsilateral breast tumor event, salvage mastectomy is the standard of care while second conservative treatment is a possible option. However, level 1 proofs are missing, leading to perform salvage mastectomy for patients who could receive second conservative treatment and consequently avoid psychological/quality of life salvage mastectomy deleterious impacts. A phase 3 randomized trial comparing salvage mastectomy to second conservative treatment is needed. Here we discuss what would be to us the optimal design of such trial to confirm the non-inferiority between the two salvage options, with a focus on methodological aspects in terms of patient characteristics and statistical issues.
{"title":"Management of second ipsilateral breast tumor event: An advocacy for a randomized trial.","authors":"J-M Hannoun-Lévi, A Savignoni, J-G Féron, C Malhaire, C Ezzili, A Brédart, P Loap, Y Kirova","doi":"10.1016/j.canrad.2023.11.001","DOIUrl":"https://doi.org/10.1016/j.canrad.2023.11.001","url":null,"abstract":"<p><p>For a second ipsilateral breast tumor event, salvage mastectomy is the standard of care while second conservative treatment is a possible option. However, level 1 proofs are missing, leading to perform salvage mastectomy for patients who could receive second conservative treatment and consequently avoid psychological/quality of life salvage mastectomy deleterious impacts. A phase 3 randomized trial comparing salvage mastectomy to second conservative treatment is needed. Here we discuss what would be to us the optimal design of such trial to confirm the non-inferiority between the two salvage options, with a focus on methodological aspects in terms of patient characteristics and statistical issues.</p>","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139432769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-21DOI: 10.1101/2022.06.20.22276551
Z. Xu
Background: For treatment of esophageal carcinoma, the optimal postoperative radiotherapy target volume after three-field lymph node dissection(3-FLD) had not been determined. We analyzed local recurrence pattern of thoracic esophageal carcinoma and risk factors of lymph node recurrence after 3-FLD without prophylactic radiotherapy. Methods: We reviewed 1282 patients with thoracic esophageal squamous cell carcinoma(ESCC) who were treated with 3-FLD without radiotherapy from 2010 to 2018 and analysed local recurrence patterns and risk factors of lymph node recurrence, in order to provide a reference for determination of the radiotherapy target volume for thoracic ESCC. Results: The lymph node recurrence accounted for 91.0% of treatment failures. The mediastinal, cervical and abdominal lymph node recurrence rates were 85.2%, 36.5% and 22.4%, respectively,(x 2 =264.596, P=0.000). The superior, middle and inferior mediastinal lymph node recurrence rates were 67.54%, 27.87% and 0.98%, respectively(x 2 =313.600, P=0.000). In a multivariate analysis, Cevical metastases were significantly associated with N stage and Preoperative cevical lymph node status. Abdominal metastases were significantly associated with the number of preoperative abdominal lymph node metastases( LNM), tumor location and N stage. Conclusions: The main pattern of local-regional recurrence might be lymph node metastasis after radical 3-FLD without radiotherapy in esophageal carcinoma. The dangerous lymph node recurrence regions included neck, superior and middle mediastinum. Radiologist might took the number of pre-operative abdominal lymph nodes and tumor location into consideration while delineating the target area of abdominal region .
{"title":"Pattern of relapse following three-field lymphadenectomy of esophageal carcinoma and related factors predictive of recurrence","authors":"Z. Xu","doi":"10.1101/2022.06.20.22276551","DOIUrl":"https://doi.org/10.1101/2022.06.20.22276551","url":null,"abstract":"Background: For treatment of esophageal carcinoma, the optimal postoperative radiotherapy target volume after three-field lymph node dissection(3-FLD) had not been determined. We analyzed local recurrence pattern of thoracic esophageal carcinoma and risk factors of lymph node recurrence after 3-FLD without prophylactic radiotherapy. Methods: We reviewed 1282 patients with thoracic esophageal squamous cell carcinoma(ESCC) who were treated with 3-FLD without radiotherapy from 2010 to 2018 and analysed local recurrence patterns and risk factors of lymph node recurrence, in order to provide a reference for determination of the radiotherapy target volume for thoracic ESCC. Results: The lymph node recurrence accounted for 91.0% of treatment failures. The mediastinal, cervical and abdominal lymph node recurrence rates were 85.2%, 36.5% and 22.4%, respectively,(x 2 =264.596, P=0.000). The superior, middle and inferior mediastinal lymph node recurrence rates were 67.54%, 27.87% and 0.98%, respectively(x 2 =313.600, P=0.000). In a multivariate analysis, Cevical metastases were significantly associated with N stage and Preoperative cevical lymph node status. Abdominal metastases were significantly associated with the number of preoperative abdominal lymph node metastases( LNM), tumor location and N stage. Conclusions: The main pattern of local-regional recurrence might be lymph node metastasis after radical 3-FLD without radiotherapy in esophageal carcinoma. The dangerous lymph node recurrence regions included neck, superior and middle mediastinum. Radiologist might took the number of pre-operative abdominal lymph nodes and tumor location into consideration while delineating the target area of abdominal region .","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90169296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-01DOI: 10.1016/j.canrad.2022.01.004
M. Maitre, T. Gupta, P. Maitre, Ayan Chatterjee, A. Dasgupta, A. Moiyadi, P. Shetty, S. Epari, A. Sahay, V. Patil, R. Krishnatry, G. Sastri, R. Jalali
{"title":"High-dose salvage re-irradiation in recurrent/progressive adult diffuse gliomas: development of a novel prognostic scoring system.","authors":"M. Maitre, T. Gupta, P. Maitre, Ayan Chatterjee, A. Dasgupta, A. Moiyadi, P. Shetty, S. Epari, A. Sahay, V. Patil, R. Krishnatry, G. Sastri, R. Jalali","doi":"10.1016/j.canrad.2022.01.004","DOIUrl":"https://doi.org/10.1016/j.canrad.2022.01.004","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72668015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-01DOI: 10.1016/j.canrad.2022.01.002
M. Rom, R. Schott, E. Pencreac'h, H. Cebula, D. Cox, L. Bender, D. Antoni, B. Lhermitte, G. Noel
{"title":"[Impact of NGS results on patient outcome with a multiform glioblastoma].","authors":"M. Rom, R. Schott, E. Pencreac'h, H. Cebula, D. Cox, L. Bender, D. Antoni, B. Lhermitte, G. Noel","doi":"10.1016/j.canrad.2022.01.002","DOIUrl":"https://doi.org/10.1016/j.canrad.2022.01.002","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83478540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-01DOI: 10.1016/j.canrad.2021.10.009
R. Asso, Fabiana A M Degrande, J. L. Fernandes da Silva, E. Leite
{"title":"Postoperative radiotherapy in prostate cancer: When and how? - An update review.","authors":"R. Asso, Fabiana A M Degrande, J. L. Fernandes da Silva, E. Leite","doi":"10.1016/j.canrad.2021.10.009","DOIUrl":"https://doi.org/10.1016/j.canrad.2021.10.009","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82483287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1016/j.canrad.2021.12.009
A. Barcellini, A. Mirandola, M. R. Fiore, E. Orlandi, L. Cobianchi
{"title":"Omentum flap as a spacer before carbon ion radiotherapy for gynecological recurrences. A technical note.","authors":"A. Barcellini, A. Mirandola, M. R. Fiore, E. Orlandi, L. Cobianchi","doi":"10.1016/j.canrad.2021.12.009","DOIUrl":"https://doi.org/10.1016/j.canrad.2021.12.009","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74797756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1016/j.canrad.2021.12.007
G. Dupic, C. Delmaire, J. Savatovsky, A. Kourilsky
{"title":"[Role of tractography in stereotactic radiosurgery and brain stereotactic radiotherapy].","authors":"G. Dupic, C. Delmaire, J. Savatovsky, A. Kourilsky","doi":"10.1016/j.canrad.2021.12.007","DOIUrl":"https://doi.org/10.1016/j.canrad.2021.12.007","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77212669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-03-31DOI: 10.21203/RS.3.RS-353943/V1
G. Duo, Jilong Feng, E. Zhang, Li-jun Wang
PUPOSE To evaluate the impact of postoperative radiotherapy (PORT) on survival in olfactory neuroblastoma (ONB) patients with different tumor staging. MATERIAL AND METHODS Patients with ONB were selected in the Surveillance, Epidemiology and End Results (SEER) database from 2004-2016. Survival analyses were performed using Kaplan-Meier (K-M) method, Cox regression analysis, and competing risk model. RESULTS A total of 513 patients were included in the study. Univariate and multivariate analysis results demonstrated that PORT was not an independent prognostic factor for overall survival (OS) of modified Kadish stage A and B patients (P=0.699 and P=0.248, respectively). Kadish stage C and D patients who underwent PORT had significantly better OS than those who did not undergo PORT (P=0.03 and P<0.0001). K-M curves revealed that the 5- and 10-year OS rates of patients who underwent PORT vs. non-PORT were 85.3% vs. 70.4% and 68.2% vs. 56.8% in stage C patients, respectively. For stage D patients, the 5-year OS rates were 70.7% and 42.6%, and 10-year OS rates were 53.4% and 29.5% in the PORT and non-PORT groups, respectively. The competitive risk model revealed that the 5-year cancer-specific cumulative mortality incidence decreased by 26.6% while the 10-year mortality incidence decreased by 41.4% in Kadish stage C patients who were treated using PORT; meanwhile, for Kadish stage D patients who were treated with PORT, the 5- and 10-year mortality incidences were reduced by 35.3% and 42.6%, respectively. Furthermore, we found that chemotherapy was not related to the prognosis of ONB patients (all P>0.05). CONCLUSION Our results indicate that PORT improved survival outcomes of modified Kadish stage C and D ONB patients. However, PORT may not affect survival for modified Kadish stage A and B individuals. Chemotherapy was not recommended for ONB; therefore, further studies are warranted to determine its therapeutic significance.
{"title":"Survival impact of postoperative radiotherapy in patients with olfactory neuroblastoma: 513 cases from the SEER database.","authors":"G. Duo, Jilong Feng, E. Zhang, Li-jun Wang","doi":"10.21203/RS.3.RS-353943/V1","DOIUrl":"https://doi.org/10.21203/RS.3.RS-353943/V1","url":null,"abstract":"PUPOSE\u0000To evaluate the impact of postoperative radiotherapy (PORT) on survival in olfactory neuroblastoma (ONB) patients with different tumor staging.\u0000\u0000\u0000MATERIAL AND METHODS\u0000Patients with ONB were selected in the Surveillance, Epidemiology and End Results (SEER) database from 2004-2016. Survival analyses were performed using Kaplan-Meier (K-M) method, Cox regression analysis, and competing risk model.\u0000\u0000\u0000RESULTS\u0000A total of 513 patients were included in the study. Univariate and multivariate analysis results demonstrated that PORT was not an independent prognostic factor for overall survival (OS) of modified Kadish stage A and B patients (P=0.699 and P=0.248, respectively). Kadish stage C and D patients who underwent PORT had significantly better OS than those who did not undergo PORT (P=0.03 and P<0.0001). K-M curves revealed that the 5- and 10-year OS rates of patients who underwent PORT vs. non-PORT were 85.3% vs. 70.4% and 68.2% vs. 56.8% in stage C patients, respectively. For stage D patients, the 5-year OS rates were 70.7% and 42.6%, and 10-year OS rates were 53.4% and 29.5% in the PORT and non-PORT groups, respectively. The competitive risk model revealed that the 5-year cancer-specific cumulative mortality incidence decreased by 26.6% while the 10-year mortality incidence decreased by 41.4% in Kadish stage C patients who were treated using PORT; meanwhile, for Kadish stage D patients who were treated with PORT, the 5- and 10-year mortality incidences were reduced by 35.3% and 42.6%, respectively. Furthermore, we found that chemotherapy was not related to the prognosis of ONB patients (all P>0.05).\u0000\u0000\u0000CONCLUSION\u0000Our results indicate that PORT improved survival outcomes of modified Kadish stage C and D ONB patients. However, PORT may not affect survival for modified Kadish stage A and B individuals. Chemotherapy was not recommended for ONB; therefore, further studies are warranted to determine its therapeutic significance.","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84268542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-08DOI: 10.1016/j.canrad.2020.12.006
J. Lagrange
{"title":"[Claude-Michel Lalanne (1919-2017)].","authors":"J. Lagrange","doi":"10.1016/j.canrad.2020.12.006","DOIUrl":"https://doi.org/10.1016/j.canrad.2020.12.006","url":null,"abstract":"","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74595860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-10-09DOI: 10.21203/rs.3.rs-88713/v1
Jialin Yu, Chang-lu Wang, Yuan Liu, Jia-ming Wang, C. Lv, Jun Liu, Zhang Qin, X. Fu, Xuwei Cai
PURPOSE To identify the valuable predictors of grade≥2 radiation pneumonitis (RP) in patient treated with radiotherapy after pneumonectomy for non-small cell lung cancer (NSCLC); and to construct a nomogram predicting the incidence of grade≥2 RP in such patients. PATIENTS AND METHODS We reviewed 82 patients with NSCLC received radiotherapy after pneumonectomy from 2008 to 2018. The endpoint was grade≥2 RP. Univariate and multivariate regression analysis were conducted to evaluate significant factors of grade≥2 RP. Receiver operating characteristic (ROC) curve was used to establish optimal cutoff values and the nomogram was built to make the predictive model visualized. Descriptive analysis was performed on 5 patients with grade 3 RP. RESULTS A total of 22(26.8%) patients developed grade 2 RP and 5(6.1%) patients were grade 3 RP. V5, V10, V20, V30, MLD, PTV, and PTV/TLV were associated with the occurrence of grade≥2 RP in univariate analysis, while none of the clinical factors was significant; V5(OR,1.213;95%CI,1.099-1.339; P<0.001) and V20(OR,1.435;95%CI,1.166-1.765; P=0.001) were the independent significant predictors by multivariate analysis and were included in the nomogram. The ROC analysis for the cutoff values for predicting grade≥2 RP were V5>23% (AUC=0.819, sensitivity:0.701, specificity:0.832) and V20>8% (AUC=0.812, sensitivity:0.683, specificity:0.811). Additionally, grade≥3 RP did not occur when V5<30%, V20<13% and MLD<751.2cGy, respectively. CONCLUSIONS Our study showed that V5 and V20 were independent predictors for grade≥2 RP in NSCLC patients receiving radiotherapy after pneumonectomy. Grade 3 RP did not occur whenV5<30%, V20<13% and MLD<751.2cGy, respectively. In addition, patient underwent right pneumonectomy may have a lower tolerance to radiation compared to left pneumonectomy.
目的探讨非小细胞肺癌(NSCLC)全肺切除术后放疗患者发生≥2级放射性肺炎(RP)的有价值预测因素;并构建预测此类患者≥2级RP发生率的nomogram。患者与方法回顾性分析了2008年至2018年收治的82例非小细胞肺癌全肺切除术后放疗患者。终点为≥2级RP。采用单因素和多因素回归分析评价RP≥2级的显著性因素。采用受试者工作特征(ROC)曲线建立最佳截止值，并建立nomogram使预测模型可视化。对5例3级RP患者进行描述性分析。结果2级RP 22例(26.8%)，3级RP 5例(6.1%)。在单因素分析中，V5、V10、V20、V30、MLD、PTV、PTV/TLV与≥2级RP的发生相关，而临床因素均无统计学意义;V5(优势比,1.213;95%置信区间,1.099 - -1.339;P23% (AUC=0.819，敏感性:0.701，特异性:0.832)，V20>8% (AUC=0.812，敏感性:0.683，特异性:0.811)。此外，V5<30%、V20<13%和MLD<751.2 g gy时，均未发生≥3级RP。结论我们的研究表明V5和V20是肺切除术后接受放疗的非小细胞肺癌患者≥2级RP的独立预测因子。当v5 <30%， V20<13%， MLD<751.2 g gy时，未发生3级RP。此外，与左侧全肺切除术相比，右侧全肺切除术患者对放射的耐受性可能较低。
{"title":"Study of the predictors for radiation pneumonitis in patient with non-small cell lung cancer received radiotherapy after pneumonectomy.","authors":"Jialin Yu, Chang-lu Wang, Yuan Liu, Jia-ming Wang, C. Lv, Jun Liu, Zhang Qin, X. Fu, Xuwei Cai","doi":"10.21203/rs.3.rs-88713/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-88713/v1","url":null,"abstract":"PURPOSE\u0000To identify the valuable predictors of grade≥2 radiation pneumonitis (RP) in patient treated with radiotherapy after pneumonectomy for non-small cell lung cancer (NSCLC); and to construct a nomogram predicting the incidence of grade≥2 RP in such patients.\u0000\u0000\u0000PATIENTS AND METHODS\u0000We reviewed 82 patients with NSCLC received radiotherapy after pneumonectomy from 2008 to 2018. The endpoint was grade≥2 RP. Univariate and multivariate regression analysis were conducted to evaluate significant factors of grade≥2 RP. Receiver operating characteristic (ROC) curve was used to establish optimal cutoff values and the nomogram was built to make the predictive model visualized. Descriptive analysis was performed on 5 patients with grade 3 RP.\u0000\u0000\u0000RESULTS\u0000A total of 22(26.8%) patients developed grade 2 RP and 5(6.1%) patients were grade 3 RP. V5, V10, V20, V30, MLD, PTV, and PTV/TLV were associated with the occurrence of grade≥2 RP in univariate analysis, while none of the clinical factors was significant; V5(OR,1.213;95%CI,1.099-1.339; P<0.001) and V20(OR,1.435;95%CI,1.166-1.765; P=0.001) were the independent significant predictors by multivariate analysis and were included in the nomogram. The ROC analysis for the cutoff values for predicting grade≥2 RP were V5>23% (AUC=0.819, sensitivity:0.701, specificity:0.832) and V20>8% (AUC=0.812, sensitivity:0.683, specificity:0.811). Additionally, grade≥3 RP did not occur when V5<30%, V20<13% and MLD<751.2cGy, respectively.\u0000\u0000\u0000CONCLUSIONS\u0000Our study showed that V5 and V20 were independent predictors for grade≥2 RP in NSCLC patients receiving radiotherapy after pneumonectomy. Grade 3 RP did not occur whenV5<30%, V20<13% and MLD<751.2cGy, respectively. In addition, patient underwent right pneumonectomy may have a lower tolerance to radiation compared to left pneumonectomy.","PeriodicalId":93921,"journal":{"name":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77014012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号